[SpicyIP Tidbit] Patent’s Gone, War’s On: Inside Novo Nordisk’s Semaglutide Litigation Blitz
Yesterday, Khushi and I wrote on the Semaglutide patent expiry and what it could mean for Indian generic companies and the general public. And while the market is seeing more affordable versions of the drug, a separate story is taking place in the Delhi High Court with Novo Nordisk filing a fresh set of trademark and patent infringement suits against generic companies. The Ozempic Name Game: Novo Nordisk v. DRL Round 2 On Semaglutide injections, Novo Nordisk has filed a […]









